FENNEC PHARMACEUTICALS INC
FENCNASDAQTrading Snapshot
- Day Range
- $10.70 – $11.25
- 52-Week Range
- $5.65 – $13.25
- Volume (shares)
- 180,560
- Avg Volume (shares)
- —
- Shares Outstanding
- 35.1M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $45M
- Last Q Revenue
- $18M
- P/E Ratio
- —
- P/S Ratio
- 6.4x
- EPS (TTM)
- $-0.12
- Dividend Yield
- —
- Dilution (1yr)
- +13.5%
FENNEC PHARMACEUTICALS INC
FENC
StockOtter · stockotter.spaceAbout FENNEC PHARMACEUTICALS INC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Adherex Technologies Inc. (NASDAQ:FENC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock w
Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey
Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in rai
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Adherex Technologies Q2 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its